Loading...
Market
Story
Hims & Hers Adds $199 GLP-1 Injections to Weight Loss Program, Stock Surges 38%
May 20, 2024, 06:33 PM
Hims & Hers Health announced that it will add compounded GLP-1 injections to its weight loss program. These injections, similar to popular drugs like Ozempic and Wegovy, will be offered at a significantly lower price of $199, compared to nearly $1,000 for the branded versions. The announcement has led to a surge in Hims & Hers' stock, which has increased by as much as 38%, including a 10%, 20%, and 30% rise throughout the day, reaching a three-year high. This move aims to provide affordable weight-loss solutions through the company's telehealth platform, despite concerns over the FDA approval status of compounded drugs. The new offering is part of Hims & Hers' broader strategy to compete with big pharmaceutical companies by providing cost-effective alternatives.
View original story
Similar markets
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Below 5% • 25%
5-10% • 25%
11-15% • 25%
Above 15% • 25%
Below 50% satisfaction • 25%
50% to 70% satisfaction • 25%
70% to 90% satisfaction • 25%
Above 90% satisfaction • 25%
0 partnerships • 25%
1 partnership • 25%
2 partnerships • 25%
3 or more partnerships • 25%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Ozempic >50% • 25%
Ozempic 25-50% • 25%
Ozempic <25% • 25%
Other brands dominate • 25%
Decrease • 25%
No Change • 25%
Increase up to 5% • 25%
Increase more than 5% • 25%